Alan Whitmore

Chief Scientific Officer

e-Therapeutics PLC

Alan Whitmore is Chief Scientific Officer at e-Therapeutics PLC. He moved from academia into biotech 12 years ago and has worked in both drug delivery and drug discovery. 

Stephanos Ioannidis

Vice President, Head of Chemistry

H3 Biomedicine

Dr. Stephanos Ioannidis obtained his B.Sc. at King's College London in chemistry and biochemistry before moving to Imperial College London

Alister Campbell

Global Head of Application Science

Dotmatics

Alister Campbell is the Global Head of Application Science at Dotmatics.

Christopher J Tame

Senior Principle Scientist

BenevolentAI

Chris is a medicinal chemist working across Target ID and early discovery chemistry at Benevolent AI.

Davide Gianni

Associate Director

Astrazeneca

Davide Gianni currently leads the Functional Genomics team in Discovery Sciences (AZ) in Cambridge UK.

​Javier Terriente

CSO

ZeClinics

Javier is Chief Scientific Officer (CSO) and co-founder at ZeClinics. He is an expert in zebrafish biology and the exploitation of this animal model for drug discovery purposes.

Jonathan Hall

Professor of Pharmaceutical Chemistry

Eth Zurich

In 2012 JH served as Chairman of the Institute of Pharmaceutical Sciences (IPW).

Rob Howes

Director of Discovery Biology & Discovery Sciences

AstraZeneca

Rob has been at AstraZeneca since 2016 where he leads the Discovery Biology department part of the Innovative Medicines organisation.

​Amaury Fernandez

Head of Compound Screening

SERVIER

Amaury E. Fernández-Montalván is the Head of Compound Screening at the SERVIER Research Institute since March 2018.

Matthias Frech

Director Molecular Interactions and Biophysics

Merck Serono

Dr. Matthias Frech is currently the Head of the Department for Molecular Interaction and Biophysics (MIB) at Merck.

Nikolaus Krall

Managing Director

Allcyte GmbH

Nikolaus Krall is a Vienna, Austria based biotech entrepreneur with a passion for translating cutting edge innovation from bench to bedside.

Jo Varshney

Founder & CEO

VeriSIM Life

Dr. Varshney’s research and development expertise are diverse, and encompasses physiology and medicine (DVM), computational biology and machine learning/artificial intelligence (ML/AI) (PhD).

Maria Waldhoer

Chief Scientific Officer

InterAx Biotech AG

Dr. Waldhoer has a 25+ year experience both in academia and industry in Europe and the US, working in early R&D project management and drug discovery.

Jonathan S Mason

Senior Research Fellow

Sosei Heptares

Dr Jonathan S Mason is a Senior Research Fellow at Sosei Heptares for GPCR structure-based drug design and a Scientific Advisor to several innovative biotech companies

Pilar Pizcueta

Director of Biology

Minoryx Therapeutics

Pilar holds a PhD in Pharmacy from the Universitat de Barcelona. Supported by a Fulbright Postdoctoral Fellowship she worked at Harvard Medical School and later at Duke’s University, Durham (USA).

Kenneth Barr

Sr. Vice President – Discovery Services

Syngene

Kenneth holds a Ph.D. in Synthetic Organic/Organometallic Chemistry from Massachusetts Institute of Technology and has pursued his Postdoctoral study in Natural product synthesis

Vivek K Vishnudas

Sr Vice President

Berg LLC

As Senior Vice President, Drug Discovery and Platform Sciences, Vivek Vishnudas, oversees the development of experimental therapeutics from conception and drug discovery to first-in-human studies.

Sven Nahnsen

Director

Quantitative Biology Center - QBiC

High-throughput technologies generate an ever increasing amount of biological and medical data

Hubert Haag

Director BD&L Research Platforms

Sanofi

In the new Sanofi R&D organization, H. Haag is responsible for sourcing and external business within the Lead Generation department and is a member of its leadership team.

Oleg Fedorov

Group Head

University of Oxford

Open Chemical Tools for Discovery and Validation of novel Drug Targets.

Immanuel Lerner

CEO, co-founder

Pepticom

Scientist and Biotech entrepreneur with a proven track record in envisioning and establishing a successful AI/biotech startup.

Dora Barna

Application Scientist

ChemAxon

Dora Barna received her MSc degree in Chemistry in 2009, and PhD degree in Theoretical Chemistry in 2013 from the University of Szeged, Faculty of Science and Informatics, in Hungary.

Jose Duca

Global Head of Computer-Aided Drug Discovery

Novartis

José is Global Head of Computer Aided Drug Discovery (CADD), part of
Global Discovery Chemistry at the Novartis Institutes for BioMedical
Research (NIBR).

Alun McCarthy

VP Novel Target Biology and Genomics

C4X Discovery

Alun is currently VP Novel Target Biology and Genomics at C4X Discovery. He has over 35 years experience in pharmaceutical R&D, including drug discovery and genetics research.

Peter Hamley

Global Head, External Innovation, Drug Discovery Platforms

Sanofi

Experienced leader and manager in complex cross-functional R&D and BD organisations of top pharmacompanies

Hanneke Later-Nijland

Attorney At Law

Axon Lawyers

Hanneke is the only lawyer-pharmacist in the Netherlands. She specializes in EU and national (bio)pharma law.

Philip Tagari

VP of Research

AMGEN

Philip Tagari is currently Vice President of Research (Therapeutic Discovery) at Amgen Inc, the world’s largest independent biotechnology company.

Martin Akerman

CTO, Co-founder

Envisagenics

Dr. Martin Akerman is a data scientist trained in biology and computer science with a PhD from Technion (Israel) and a post doctorate from Cold Spring Harbor Laboratory (CSHL).

Paul Beswick

Director of UK Chemistry and IP

Bicycle Therapeutics

Paul Beswick is a Medicinal Chemist with over 30 years experience both in industry and university drug discovery groups.

Markus Muellner

Chief Technology Officer

PhoreMost Ltd

Markus is a data scientist with a background functional genetic screening, engineering and bioinformatics and is leading the screening group and bioinformatics team at PhoreMost